Share on LinkedInShare on LinkedIn

ARTICLE · 14 OCTOBER 2026

When AI Designs The Ingredient: Who Controls The Data, The Model And The Discovery?

As artificial intelligence transforms ingredient discovery across pharmaceuticals, food, and biotechnology, companies face a critical challenge: when multiple organizations contribute data, AI models, and expertise to create new molecules and insights, who controls the resulting intellectual property? The answer requires rethinking traditional IP frameworks to account for datasets, model improvements, and experimental knowledge that may prove more valuable than the initial products themselves.

United KingdomIntellectual Property

AI-enabled discovery has drawn significant attention in pharmaceutical R&D, but its impact is extending into other industries, across ingredients, food, flavour, fragrance and industrial biotechnology. As AI models advance, the key developments are not just new applications of AI, but new innovation models in which different companies contribute different parts of the discovery engine.

One company may bring an AI model; another proprietary data and domain expertise; and both may contribute to experimental validation and commercial scale-up. The collaboration should therefore be viewed not simply as a route to a defined product, but as a discovery engine. It may ultimately deliver a new molecule or ingredient, while also creating new datasets, model improvements, experimental insights and process know-how (DSM-Firmenich, 2026), (Nasdaq, 2026).

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from